Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

LGBTQ+

- PMLiVE

Research Partnership launches Access CGT

Research Partnership’s specialist market access team have launched Access CGT, a new syndicated access and policy tracker providing surveillance of the cell and gene therapy space.Read more

Inizio

- PMLiVE

Innovation in Education Leads to Positive Outcomes at EAN 2023

The Medscape team recently returned from the 9th Annual Congress of the European Academy of Neurology (EAN) in Budapest, Hungary. Among the various highlights of the congress, the team showcased...

Medscape Education

- PMLiVE

AstraZeneca and Daiichi Sankyo share positive results from phase 3 lung cancer study

The investigational drug met the dual primary endpoint of progression-free survival

- PMLiVE

Boehringer’s spesolimab shows promise in generalised pustular psoriasis prevention

The therapy prevented flares in patients with the chronic skin disease for over 48 weeks

- PMLiVE

Sandoz launches high-concentration biosimilar of AbbVie’s Humira in the US

Hyrimoz HCF is approved to treat indications including rheumatoid arthritis and Crohn’s disease

- PMLiVE

Return on investment

If we are being asked to demonstrate ROI, we first need to agree on the value of the outcome

- PMLiVE

Novartis to sell eye-care products to Bausch + Lomb in deal worth up to $2.5bn

The transaction includes the Swiss drugmaker’s anti-inflammatory eye drop Xiidra

- PMLiVE

Roche’s Evrysdi shows continued improvement in children with spinal muscular atrophy

The progressive neuromuscular disease affects approximately one in every 10,000 babies

- PMLiVE

AI – the next paradigm shift in healthcare

How to create healthy ecosystems for positive progress

- PMLiVE

Eli Lilly to acquire Sigilon in deal worth over $300m

The companies have been working together since 2018 on cell therapies for type 1 diabetes

- PMLiVE

FDA approves BioMarin’s Roctavian as first gene therapy for severe haemophilia A

Approximately 2,500 patients are expected to be eligible to receive the one-time therapy

- PMLiVE

AstraZeneca’s phase 3 liver cancer study shows continued survival benefit

Hepatocellular carcinoma accounts for about 75% of all primary liver cancers in adults

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links